Laura Iezzi

960 total citations
21 papers, 411 citations indexed

About

Laura Iezzi is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Laura Iezzi has authored 21 papers receiving a total of 411 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 6 papers in Cancer Research and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Laura Iezzi's work include Breast Cancer Treatment Studies (6 papers), Advanced Breast Cancer Therapies (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Laura Iezzi is often cited by papers focused on Breast Cancer Treatment Studies (6 papers), Advanced Breast Cancer Therapies (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Laura Iezzi collaborates with scholars based in Italy, Malaysia and United Kingdom. Laura Iezzi's co-authors include Clara Natoli, Antonino Grassadonia, Nicola Tinari, Patrizia Vici, Laura Pizzuti, Maddalena Barba, Teresa Gamucci, Michele De Tursi, Vincenzo Graziano and Isabella Sperduti and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Laura Iezzi

21 papers receiving 406 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura Iezzi Italy 11 308 102 84 79 76 21 411
Débora S. Bruno United States 12 215 0.7× 82 0.8× 77 0.9× 128 1.6× 51 0.7× 45 352
Luis Z. Blanco United States 11 165 0.5× 64 0.6× 63 0.8× 74 0.9× 69 0.9× 32 358
Alison Lannigan United Kingdom 8 234 0.8× 106 1.0× 47 0.6× 61 0.8× 53 0.7× 21 325
Yalun Li China 12 164 0.5× 89 0.9× 82 1.0× 163 2.1× 117 1.5× 39 412
Adher Alsayed Saudi Arabia 10 173 0.6× 111 1.1× 58 0.7× 33 0.4× 55 0.7× 19 304
Karl Verpoort Germany 7 222 0.7× 98 1.0× 123 1.5× 53 0.7× 64 0.8× 10 370
Melinda Laine Hsu United States 11 214 0.7× 44 0.4× 111 1.3× 119 1.5× 160 2.1× 28 422
Elisa García-Garré Spain 8 392 1.3× 175 1.7× 110 1.3× 62 0.8× 122 1.6× 16 547
Nancy Nixon Canada 10 233 0.8× 43 0.4× 85 1.0× 69 0.9× 64 0.8× 26 348
Αngeliki Andrikopoulou Greece 13 220 0.7× 78 0.8× 30 0.4× 89 1.1× 158 2.1× 41 438

Countries citing papers authored by Laura Iezzi

Since Specialization
Citations

This map shows the geographic impact of Laura Iezzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Iezzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Iezzi more than expected).

Fields of papers citing papers by Laura Iezzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Iezzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Iezzi. The network helps show where Laura Iezzi may publish in the future.

Co-authorship network of co-authors of Laura Iezzi

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Iezzi. A scholar is included among the top collaborators of Laura Iezzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Iezzi. Laura Iezzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grassadonia, Antonino, Vincenzo Graziano, Laura Iezzi, et al.. (2021). Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. Cells. 10(7). 1685–1685. 28 indexed citations
2.
3.
Peri, Marta, Antonino Grassadonia, Laura Iezzi, et al.. (2019). A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression. SHILAP Revista de lepidopterología. 2019. 1–4. 2 indexed citations
4.
5.
6.
Grassadonia, Antonino, Isabella Sperduti, Patrizia Vici, et al.. (2018). Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. Journal of Clinical Medicine. 7(12). 542–542. 70 indexed citations
7.
8.
Barba, Maddalena, Patrizia Vici, Laura Pizzuti, et al.. (2017). Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. BMC Cancer. 17(1). 101–101. 7 indexed citations
9.
Grassadonia, Antonino, Patrizia Vici, Teresa Gamucci, et al.. (2017). Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. The Breast. 32. 79–86. 11 indexed citations
10.
Ricciardi, Giuseppina Rosaria Rita, Corrado Ficorella, Laura Iezzi, et al.. (2017). Efficacy and safety of the combination of pertuzumab (P) plus trastuzumab (T) plus docetaxel (D) for HER-2 positive metastatic breast cancer (MBC) in pretreated patients (pts) with trastuzumab in the neo/adjuvant setting: A real-life study.. Journal of Clinical Oncology. 35(15_suppl). e12516–e12516. 2 indexed citations
11.
Gamucci, Teresa, Lucia Mentuccia, Isabella Sperduti, et al.. (2017). Efficacy of pertuzumab in combination with trastuzumab and a taxane in first-line treatment for metastatic breast cancer (MBC): A multicenter, retrospective, observational study.. Journal of Clinical Oncology. 35(15_suppl). e12504–e12504. 3 indexed citations
12.
Moscetti, Luca, Agnese Fabbri, Clara Natoli, et al.. (2017). Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. Oncotarget. 8(33). 54528–54536. 12 indexed citations
13.
Airoldi, Irma, Claudia Cocco, Carlo Sorrentino, et al.. (2016). Interleukin-30 Promotes Breast Cancer Growth and Progression. Cancer Research. 76(21). 6218–6229. 32 indexed citations
14.
Moscetti, Luca, Patrizia Vici, Isabella Sperduti, et al.. (2015). Safety analysis, correlation with response and previous treatments of the association of everolimus (EVE) and exemestane (EXE) in 181 metastatic breast cancer patients (MBC). Annals of Oncology. 26. vi13–vi13. 1 indexed citations
15.
Barni, Sandro, Caterina Fontanella, Lucia Del Mastro, et al.. (2015). A broad Italian experience with eribulin mesylate in metastatic breast cancer patients: The ESEMPiO study.. Journal of Clinical Oncology. 33(15_suppl). e11539–e11539. 3 indexed citations
16.
Grassadonia, Antonino, Marta Di Nicola, Domenico Angelucci, et al.. (2014). Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer. Annals of Surgical Oncology. 21(5). 1575–1582. 12 indexed citations
17.
Grassadonia, Antonino, et al.. (2013). Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers. 5(3). 919–942. 34 indexed citations
18.
Angelucci, Domenico, Nicola Tinari, Antonino Grassadonia, et al.. (2012). Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. Journal of Cancer Research and Clinical Oncology. 139(2). 269–280. 19 indexed citations
19.
Iezzi, Laura, et al.. (2009). Sequías en el sudoeste bonaerense : Vulnerabilidad e incertidumbre. SHILAP Revista de lepidopterología. 5(5). 213–233. 9 indexed citations
20.
Iezzi, Laura, et al.. (2006). 608 Impact of treatment for hepatitis C infection in clinical practice. Journal of Hepatology. 44. S226–S226. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Débora S. Bruno Breakdown of academic impact, for papers by Luis Z. Blanco Breakdown of academic impact, for papers by Alison Lannigan Breakdown of academic impact, for papers by Yalun Li Breakdown of academic impact, for papers by Adher Alsayed Breakdown of academic impact, for papers by Karl Verpoort Breakdown of academic impact, for papers by Melinda Laine Hsu Breakdown of academic impact, for papers by Elisa García-Garré Breakdown of academic impact, for papers by Nancy Nixon Breakdown of academic impact, for papers by Αngeliki Andrikopoulou
Rankless by CCL
2026